Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | HBB | P68871 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29387216 | 0.83 | UGT2B7 (0.50) | HSD17B10ALDH1A1CYP3A4HTR2AHTR2C | |
| SCHEMBL15310450 | 0.83 | UGT2B7 (0.48) | HSD17B10ALDH1A1CYP3A4HTR2AHTR2C | |
| SCHEMBL20153682 | 0.79 | TSHR (0.47) | HSD17B10ALDH1A1CYP3A4HTR2AHTR2C | |
| SCHEMBL20757041 | 0.78 | CYP1A2 (0.47) | HSD17B10CYP3A4TDP1ALOX15HIF1A | |
| SCHEMBL832810 | 0.77 | GAA (0.46) | ALDH1A1CYP3A4HTR2CHTR2BHSP90AA1 | |
| SCHEMBL10938462 | 0.77 | IDO1 (0.55) | HSD17B10ALDH1A1CYP3A4IDO1HIF1A | |
| SCHEMBL22303994 | 0.75 | CASP6 (0.57) | HSD17B10ALDH1A1HSP90AA1HSP90AB1CASP1 | |
| SCHEMBL117750 | 0.75 | PTK2 (0.41) | ALDH1A1CYP3A4HTR2CHTR2BHSP90AA1 | |
| SCHEMBL11509499 | 0.74 | CYP2A6 (0.46) | HSD17B10CYP3A4HTR2AHTR2CHTR2B | |
| SCHEMBL139321 | 0.74 | CYP3A4 (0.55) | HSD17B10ALDH1A1CYP3A4IDO1CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030853-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-20230255101-A1 | Tetradentate Metal Complexes with Carbon Group Bridging Ligands | UNIV ARIZONA STATE (US) | 2023-08-10 | — | — | US | disclosed |
| US-11653560-B2 | Tetradentate metal complexes with carbon group bridging ligands | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2023-05-16 | — | — | US | disclosed |
| US-20230015063-A1 | METAL-ASSISTED DELAYED FLUORESCENT EMITTERS CONTAINING TRIDENTATE LIGANDS | UNIV ARIZONA STATE (US) | 2023-01-19 | — | — | US | disclosed |
| US-20220162209-A1 | SALICYL-ADENOSINEMONOSULFAMATE ANALOGS AND USES THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2022-05-26 | — | — | US | disclosed |
| US-20210379190-A1 | FAP-ACTIVATED PROTEASOME INHIBITORS FOR TREATING SOLID TUMORS | TRUSTEES OF TUFTS COLLEGE | 2021-12-09 | — | — | US | disclosed |
| US-11145830-B2 | Metal-assisted delayed fluorescent emitters containing tridentate ligands | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2021-10-12 | — | — | US | disclosed |
| US-11065339-B2 | FAP-activated proteasome inhibitors for treating solid tumors | TRUSTEES OF TUFTS COLLEGE (US) | 2021-07-20 | — | — | US | disclosed |
| US-20210171461-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2021-06-10 | — | — | US | disclosed |
| US-20210126208-A1 | Tetradentate Metal Complexes with Carbon Group Bridging Ligands | UNIV ARIZONA STATE (US) | 2021-04-29 | — | — | US | disclosed |
| US-20180159051-A1 | EMITTERS BASED ON OCTAHEDRAL METAL COMPLEXES | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2018-06-07 | — | — | US | disclosed |
| US-20180148464-A1 | TETRADENTATE AND OCTAHEDRAL METAL COMPLEXES CONTAINING NAPHTHYRIDINOCARBAZOLE AND ITS ANALOGUES | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2018-05-31 | — | — | US | disclosed |
| US-20180138428-A1 | METAL-ASSISTED DELAYED FLUORESCENT EMITTERS CONTAINING TRIDENTATE LIGANDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2018-05-17 | — | — | US | disclosed |
| US-9956297-B2 | FAP-activated proteasome inhibitors for treating solid tumors | TRUSTEES OF TUFTS COLLEGE (US) | 2018-05-01 | — | — | US | disclosed |
| US-9956297-B2 | FAP-activated proteasome inhibitors for treating solid tumors | TRUSTEES OF TUFTS COLLEGE (US) | 2018-05-01 | — | — | US | disclosed |
| US-9879039-B2 | Tetradentate and octahedral metal complexes containing naphthyridinocarbazole and its analogues | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-01-30 | — | — | US | disclosed |
| US-9818959-B2 | Metal-assisted delayed fluorescent emitters containing tridentate ligands | Arizona Board of Regents on behlaf of Arizona State University (US) | 2017-11-14 | — | — | US | disclosed |
| US-9597410-B2 | FAP-activated proteasome inhibitors for treating solid tumors | TRUSTEES OF TUFTS COLLEGE (US) | 2017-03-21 | — | — | US | disclosed |
| US-20170066792-A1 | TETRADENTATE AND OCTAHEDRAL METAL COMPLEXES CONTAINING NAPHTHYRIDINOCARBAZOLE AND ITS ANALOGUES | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2017-03-09 | — | — | US | disclosed |
| US-20160346401-A1 | FAP-Activated Proteasome Inhibitors for Treating Solid Tumors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210379190-A1 | FAP-ACTIVATED PROTEASOME INHIBITORS FOR TREATING SOLID TUMORS | FAP, PSMA1, PSMA6 | HSD17B10 3902/4885ALDH1A1 1095/4885CYP3A4 3117/4885 |
| US-11145830-B2 | Metal-assisted delayed fluorescent emitters containing tridentate ligands | SLC30A6, SLC30A5, BRI3BP | HSD17B10 4643/4885ALDH1A1 1393/4885CYP3A4 4434/4885 |
| US-20210126208-A1 | Tetradentate Metal Complexes with Carbon Group Bridging Ligands | STAU1, POLR1G, CLTC | HSD17B10 4816/4885ALDH1A1 3464/4885CYP3A4 4630/4885 |
| US-11065339-B2 | FAP-activated proteasome inhibitors for treating solid tumors | FAP, PSMA1, PSMA6 | HSD17B10 3902/4885ALDH1A1 1095/4885CYP3A4 3117/4885 |
| US-20230015063-A1 | METAL-ASSISTED DELAYED FLUORESCENT EMITTERS CONTAINING TRIDENTATE LIGANDS | SLC30A6, SLC30A5, BRI3BP | HSD17B10 4643/4885ALDH1A1 1393/4885CYP3A4 4434/4885 |
| US-20220162209-A1 | SALICYL-ADENOSINEMONOSULFAMATE ANALOGS AND USES THEREOF | ADSL, SLC35B2, ADORA1 | HSD17B10 3491/4885ALDH1A1 136/4885CYP3A4 2279/4885 |
| US-20180159051-A1 | EMITTERS BASED ON OCTAHEDRAL METAL COMPLEXES | POLR1G, ITPA, ERCC5 | HSD17B10 4582/4885ALDH1A1 3296/4885CYP3A4 4570/4885 |
| US-20230255101-A1 | Tetradentate Metal Complexes with Carbon Group Bridging Ligands | STAU1, POLR1G, CLTC | HSD17B10 4816/4885ALDH1A1 3464/4885CYP3A4 4630/4885 |
| US-11653560-B2 | Tetradentate metal complexes with carbon group bridging ligands | PDCD2L, STAU1, POLR1G | HSD17B10 4815/4885ALDH1A1 2789/4885CYP3A4 3834/4885 |
| US-20180138428-A1 | METAL-ASSISTED DELAYED FLUORESCENT EMITTERS CONTAINING TRIDENTATE LIGANDS | SLC30A6, SLC30A5, BRI3BP | HSD17B10 4643/4885ALDH1A1 1393/4885CYP3A4 4434/4885 |
| US-20160346401-A1 | FAP-Activated Proteasome Inhibitors for Treating Solid Tumors | FAP, PSMA1, PSMA6 | HSD17B10 3902/4885ALDH1A1 1095/4885CYP3A4 3117/4885 |
| US-20170066792-A1 | TETRADENTATE AND OCTAHEDRAL METAL COMPLEXES CONTAINING NAPHTHYRIDINOCARBAZOLE AND ITS ANALOGUES | PAICS, DNTT, PNPO | HSD17B10 3924/4885ALDH1A1 4508/4885CYP3A4 1105/4885 |
| US-20180148464-A1 | TETRADENTATE AND OCTAHEDRAL METAL COMPLEXES CONTAINING NAPHTHYRIDINOCARBAZOLE AND ITS ANALOGUES | PAICS, DNTT, PNPO | HSD17B10 3924/4885ALDH1A1 4508/4885CYP3A4 1105/4885 |
| US-12030853-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | HSD17B10 3100/4885ALDH1A1 4709/4885CYP3A4 4706/4885 |
| US-20210171461-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | HSD17B10 3100/4885ALDH1A1 4709/4885CYP3A4 4706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.